The learning curve of a biotech founder/CSO

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Hella Kohlhof, CSO at Immunic.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Hella, covering:

• How the 'waste of two molecules' led to the spin-out creation of Immunic Therapeutics.


• The perfect blend of a founding team willing to split responsibility, learn and have a go.


• Ending up as a Nasdaq-listed company via a reverse merger... and all the new challenges that came with it.


• Immunic's divide-and-conquer global outsourcing strategy, while retaining tight control.


• Examples of how geopolitical issues have impacted a biotech's growth.

Hella leads the Immunic's scientific strategy, including mode of action research, preclinical studies, and biomarker development.

Dr. Kohlhof brings deep expertise in immunology, oncology, and drug development, with previous roles at 4SC AG, where she led preclinical and clinical projects. She holds a doctorate in biology from Ludwig Maximilians University of Munich and completed her postdoc at the Helmholtz Centre, focusing on B cell development.

She holds several patents, has co-authored numerous publications, and is a regular speaker at scientific and industry events.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.